Bispecific Antibody Production

ProMab Biotechnologies has dedicated itself from the first day to develop monoclonal antibodies almost exclusively. This has given us more than 15 years of experience in antibody development and the platform required for engineering antibodies. We've expanded our capabilities to develop different antibody libraries for screening, antibody sequencing, humanization, and more.

To further ProMab’s position as a leader within antibody development, we have invested in cutting edge technology to generate custom bispecific antibodies using sophisticated engineering, in silico 3-D-modeling and synthetic biology technologies.

Starting from your idea, we can help you design, develop, and validate your bispecific antibody for research and pre-clinical positions.

 

 

Included in Custom Package

  • Sequencing and design of selected antibody clones
  • Production of bispecific antibody
  • Antibody functional validation tests
  • Sequence information for both the Heavy and Light chains.
  • Delivery of bispecific antibody
 

Background

A bispecific antibody is an antibody that includes two different antigen binding sites of monoclonal antibodies that can bind to two different antigens. There are more than 100 different designs of bispecific antibodies as described by Brinkmann et al, 2017.

Since the bispecific antibody can bind two different antigens, it can bind T cells and cancer associated antigen such as CD19-CD3 (Amgen); CEA-CD3, EpCAM-CD3 and others. Bispecific antibodies can recruit T cells by binding CD3 to cancer cells, leading to the secretion of cytokines, granzyme, perforin and ultimately leading to the killing of cancer cells (Figure 1).

 

 

Starting at $26,000

The structural type of the bispecific antibody can vary immensely. We can design any type of antibody using our gene-engineering platform and can express these antibodies in mammalian cells (such as HEK293, CHO cells) for large scale production.

Generating a bispecific antibody will need extensive experimentation for the project’s needs. ProMab’s custom bispecific antibody service includes several steps.

DEVELOPMENT STAGE DESCRIPTION COST
Phase I * Generate up to 3 sequences with different designs
Generate recombinant antibody DNA plasmid de novo
$6000
Phase II Generation of bi-specific antibody proteins.
Small-scale expression into mammalian cell lines.
Verification by SDS-page.
Binding analysis by ELISA with recombinant protein antigen.
Clones are compared to parental antibody.
$11,500
Phase III Regeneration of top 2 full length bispecific antibodies.
Binding analysis by ELISA.
ELISA evaluation of antibodies recognized by anti-mouse antibodies.
$8500
Phase IV Large scale antibody production Inquire

Additional Add-On Services

SERVICE DESCRIPTION COST
FACS Analysis Binding analysis by FACS with antigen positive cell lines. $1000
Octet BLI Binding Assay Antibody binding affinity analysis by Octet system bio-layer interferometry Inquire
BiacoreTM SPR Biosensors Binding and kinetics analysis using BiacoreTM SPR biosensors to determine antibody affinity, Ka, Kd, KD values $3200
 

 

Our Advantages

Being an antibody development company that has ventured and prevailed into the CAR-T development space, ProMab holds several advantages over our competitors.

One unique advantage ProMab offers is that we have developed many different stable cell lines with tumor antigens to validate many bispecific antibodies. For example: Hela-CD19 cells, CHO-CD22, CHO-CS1, CHO-BCMA, CHO-CD37 , and others.

ProMab has also invested in cutting-edge technology with in-vitro assays utilizing XCelligenceTM System (ACEA/Agilent), as well as an in-house animal facility for in-vivo validation.

Case Study: Bispecific Antibodies

CEA-CD3 FACS

Figure 6. CEA-CD3 bispecific antibody detects CD3 in T cells. CEA-CD3 bispecific antibody specifically recognizes CEA in CEA-positive Lovo cells. CEA-CD3 bispecific antibody does not recognize in CEA-negative/low expression cell lines HCT116 and HT29.

CEA-CD3 RTCA (+)

Figure 7. CEA-CD3 kills CEA-positive Lovo cells. RTCA assay with Lovo cells and T cells.

 

CD19-CD3 RTCA (+)

Figure 8. CD19-CD3 bispecific antibody (Amgen) kills Hela-CD19 cells in a dose-dependent manner.

CEA-CD3 (-)

Figure 7. CEA-CD3 does not kills CEA-positive Lovo without T cells as shown in RTCA assay.

>>> Bispecific Antibodies Background

Other Custom Services:

Mouse monoclonal antibodies

 
 

Human monoclonal antibodies

 
 

Hybridoma Sequencing